- https://doi.org/10.1016/s1877-1203(25)00075-8
Anticorps thérapeutiques innovants dans le cancer bronchique non à petites cellules : au-delà des cibles classiques
Abstract
Translate Article 
Take Notes
Translate Article Take Notes Anticorps thérapeutiques innovants dans le cancer bronchique non à petites cellules : au-delà des cibles classiques
ReferencesShowing 10 of 39 papersOA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50% Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. The landscape of bispecific T cell engager in cancer treatment LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study Abstract CT090: DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)
4 - 10.1016/j.jtho.2024.09.061
- Oct 1, 2024
- Journal of Thoracic Oncology
- 56
- 10.1200/jco.24.01001
- Jun 10, 2024
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 5
- 10.1016/j.iotech.2023.100593
- Dec 1, 2023
- Immuno-Oncology and Technology
- 4
- 10.1186/s40364-025-00764-4
- Mar 29, 2025
- Biomarker Research
- 26
- 10.1038/s41591-023-02385-6
- Jul 1, 2023
- Nature Medicine
- 163
- 10.1186/s40364-021-00294-9
- May 26, 2021
- Biomarker Research
- 20
- 10.1016/j.annonc.2021.10.217
- Dec 1, 2021
- Annals of Oncology
- 15
- 10.1016/j.ejca.2023.05.024
- Jun 5, 2023
- European Journal of Cancer
- 10.1158/1538-7445.am2024-ct090
- Apr 5, 2024
- Cancer Research
- 30
- 10.1016/j.lungcan.2023.107355
- Aug 29, 2023
- Lung Cancer
More from: Revue des Maladies Respiratoires ActualitésAnticorps thérapeutiques innovants dans le cancer bronchique non à petites cellules : au-delà des cibles classiques Editorial board Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable en première ligne de traitement Cancers bronchiques non à petites cellules oligo-métastatiques, oligo-persistance, oligo-progression, maladie résiduelle : de quoi parle-t-on ? Quelle prise en charge ? Éditorial : Cours du Groupe d'Oncologie Thoracique de Langue Française 2025 Sommaire Physiologie respiratoire Néoplasies neuroendocrines pulmonaires hors cancers du poumon à petites cellules : tumeurs carcinoïdes et carcinomes neuroendocrines à grandes cellules Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable au-delà de la première ligne Soins intensifs respiratoires
- Research Article
- 10.1016/s1877-1203(25)00075-8
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00014-x
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00072-2
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00070-9
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00053-9
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00051-5
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/j.rmra.2025.07.001
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00083-7
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/s1877-1203(25)00073-4
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Research Article
- 10.1016/j.rmra.2025.07.003
- Oct 1, 2025
- Revue des Maladies Respiratoires Actualités
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?